Briumvi (ublituximab-xiiy) is a prescription drug that’s used to treat certain types of multiple sclerosis (MS) in adults. Briumvi is given as an intravenous (IV) infusion by a doctor or other ...

Briumvi is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary ...

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained ...

September 2024 A button-up shirt may be your closet’s stealthiest chameleon, equally at home in a blue-chip law firm, an oonz-oonz dance club, and a Sunday farmers market. But this undeniable ...

Every product on this page was chosen by a Harper's BAZAAR editor. We may earn commission on some of the items you choose to buy. While choosing a silhouette ultimately comes down to personal ...

TG Therapeutics announced it updated its data presentations to include details from the ULTIMATE I & II Phase 3 trials, evaluating BRIUMVI. The data showed that continued use of BRIUMVI resulted ...

(RTTNews) - TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis. The company said the data ...

TG Therapeutics' Briumvi shows strong revenue growth, with Q2 2024 revenue up 350% YoY, leading to an upgraded full-year guidance of $290-$300 million. Expansion into CAR-T therapy for autoimmune ...

The trials evaluated BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) over five years. The presentations highlighted the long-term efficacy and safety of BRIUMVI ...